allergy banner

Videos


Articles


German asthma net: Nasal polyposis in patients in the severe asthma registry

Bal, C., Stoshikj, S., Milger, K., et al. Allergy. First published: 12 June 2024

Allergic inflammation triggers dyslipidemia via IgG signalling

Fernández-Gallego N, Castillo-González R, Moreno-Serna L, et al. Allergy. First published: 12 June 2024

Discovery of ILC2 extracellular traps and ILC2 ETosis: A novel feature of group 2 innate lymphoid cells

Xu, Y., Zhou, R., Yang, Y., et al. Allergy. First published: 12 June 2024

The stimulation of TH2 cells results in increased IL-5 and IL-13 production via the H4 receptor

Nikolouli E, Mommert S, Dawodu DM, et al. Allergy. First published: 10 June 2024

A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma

Madrange, M., Rossignol, J., Devin, C., et al. Allergy. First published: 08 June 2024

Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis

Bachert, C., Gevaert, P., Lipworth, B., et al. Allergy. First published: 08 June 2024

Target maintenance dose for peanut OIT is 300 mg protein (or less): Pros and cons

Upton, J. and Elizur, A. Allergy. First published: 06 June 2024

Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation

Gil-Martínez, M., Rodrigo-Muñoz, J.M., Lorente-Sorolla, C., et al. Allergy. First published: 06 June 2024

STING/RANTES pathway in airway epithelium enhances Der p1-induced airway inflammation

Tsuji, M., Kondo, M., Nishiyama, A., et al. Allergy. First published: 04 June 2024

Correspondence to “Salivary Immunoinflammatory Proteins Identify Children with Eosinophilic Esophagitis”

Votto, M., Strisciuglio, C., Indolfi, C., et al. Allergy. First published: 04 June 2024

Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions

Nakajima S, Nakamizo S, Nomura T, et al. Allergy. First published: 04 June 2024

Mapping the immune cell landscape of severe atopic dermatitis by single-cell RNA-seq

Jin S-P, Lee K, Bang YJ, et al. Allergy. First published: 31 May 2024

Skin tape-strips in old order Mennonite toddlers reveal upregulated barrier markers and low T-helper inflammatory tone

Rothenberg-Lausell, C., David, E., Del Duca, E., et al.Allergy. First published: 30 May 2024

The impact of high-salt diet on asthma in humans and mice: Effect on specific T-cell signatures and microbiome

Musiol S, Harris CP, Gschwendtner S, et al. Allergy. First published: 26 May 2024

Immunotherapy and biologics in the management of IgE-mediated food allergy: Systematic review and meta-analyses of efficacy and safety

Riggioni C, Oton T, Carmona L, Du Toit G, Skypala I, Santos AF, . Allergy. First published: 15 May 2024

Succinate induces a Th2 environment in the small intestine but does not exacerbate food allergy

Tan, J., Potier-Villette, C., Ni, D., et al. Allergy. First published: 15 May 2024

Real world study of grass pollen immunotherapy—Similar efficacy of SCIT and SLIT

Winther, L., Curtz, A.C. and Domokos, Z. Allergy. First published: 15 May 2024

Proteomics and metabolomics of sputum reveal the potential impact of allergic rhinitis on asthma

Yang, Y., Cui, L., Yu, P., et al. Allergy. First published: 11 May 2024

Meteorin-like protein/METRNL/Interleukin-41 ameliorates atopic dermatitis-like inflammation

Huang D, Liu X, Gao X, et al. Allergy. First published: 10 May 2024

Comparison of upper and lower airway expression of SARS-COV-2 receptors in allergic asthma

Ranjbar, M., Whetstone, C.E., Cusack, R.P., et al. Allergy. First published: 10 May 2024

Importance of SREBP signaling in controlling lipid metabolism and homeostasis in B cells for future vaccine design

Unger, Z., Kuklinski, A. and Gomez-Casado, C. Allergy. First published: 07 May 2024

Mouse IgE clone SPE-7 can contain functional mouse IgG

Sypka, M., Zwicker, M., Lagache, S.B., et al. Allergy. First published: 06 May 2024

Efficacy and safety of a 7-week immunotherapy protocol with aluminium hydroxide adsorbed hymenoptera venom

Kasternow, B., Kim, D.-I.S. and Yong, P.F.K. Allergy. First published: 03 May 2024

Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper

Pfaar O, Sousa-Pinto B, Papadopoulos NG, et al. Allergy. First published: 03 May 2024

Four years into the COVID-19 pandemic: Timely published articles for patient care and EAACI's leadership role

Torres, M.J., Klimek, L., Agache, I., et al. Allergy. First published: 03 May 2024

The effects of inhaled corticosteroids on healthy airways

Marchi E, Hinks TSC, Richardson M, et al. Allergy. First published: 30 April 2024

Neutrophil-driven and interleukin-36γ-associated ocular surface inflammation in chronic Stevens–Johnson syndrome

Koduri MA, Pingali T, Prasad D, et al. Allergy. First published: 29 April 2024

LPS in combination with amoxicillin increases BAT sensitivity to amoxicillin IgE-mediated hypersensitivity

Céspedes, J.A., Fernández-Santamaría, R., Bogas, G., et al. Allergy. First published: 27 April 2024

The use of omalizumab in food allergy

et al. Allergy. First published: 27 April 2024

Clovibactin: Discovery and antimicrobial mechanism of action

Pérez-Moreno, A.M., Torres, P. and Paris, J.L. Allergy. First published: 26 May 2024

Clinical applicability of AI-based prognosis prediction for a rare ocular surface disease

Ueta, M., Watanabe, Y., Melby-Thompson, C., et al. Allergy. First published: 25 April 2024

Ambient pollen exposure and pollen allergy symptom severity in the EPOCHAL study

Luyten A, Bürgler A, Glick S, et al. Allergy. First published: 24 April 2024

Citations: 342

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766

Citations: 147

EAACI guidelines: Anaphylaxis (2021 update)

Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377

Citations: 118

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990

Citations: 118

The role of peripheral blood eosinophil counts in COVID-19 patients

Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482

Citations: 114

Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease

Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449

Citations: 105

Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice

Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432

Citations: 90

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639

Citations: 88/h5>

The role of allergen-specific IgE, IgG and IgA in allergic disease

Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641

Citations: 82

COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676

Citations: 81

Advances and highlights in allergic rhinitis

Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389

Citations: 79

Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?

Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618

Citations: 76

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353

Citations: 74

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Citations: 73

Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches

Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826

Citations: 70

Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660

Citations: 69

Advances and highlights in biomarkers of allergic diseases

Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686

Citations: 69

Regulatory B cells, A to Z

Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.

Citations: 62

Advances and highlights in asthma in 2021

Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407

Citations: 62

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Citations: 61

The ingenious mast cell: Contemporary insights into mast cell behavior and function

Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99

The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414

Risk factors for severe and critically ill COVID-19 patients: A review

Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741

Advances and recent developments in asthma in 2020

Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update

Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541

Management of anaphylaxis due to COVID-19 vaccines in the elderly

Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review

Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016

Eczema herpeticum in atopic dermatitis

Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027

Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study

Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052

Direct assessment of individual skin barrier components by electrical impedance spectroscopy

Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132

Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis

Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154

Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy

Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193

Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma

Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202

Identification of Ulocladium chartarum as an important indoor allergen source

Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206

Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis

Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214

Legends of allergy and immunology: Sergio Bonini

Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229

Medical algorithm: Peri-operative management of mastocytosis patients

Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235

Open Access Agreements with Wiley



Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley

Free access

Junior Members Corner



Dear Junior Members,

The EAACI Immunology Winter School 2024 was held this year (08-11 January) in the beautiful city of Zakopane (Poland). For 4 days, 70 EAACI junior members selected for the quality of their abstracts had the opportunity to enjoy the fantastic meeting organised by the EAACI Basic and Clinical Immunology Section. They had the chance to enjoy the brilliant talks of senior experts in 6 different keynote sessions, as well as the talks of other junior colleagues in 7 different oral abstract sessions, not forgetting the poster sessions, with more than 50 posters presented. During this edition, 6 different practical courses were carried out to learn about the most relevant advances in different immunology fields in a funny way. All these scientific events were accompanied by vibrant discussions, not only during the sessions, but also during dinners, breakfast, or coffee breaks.

As usual during the Winter School, different social activities were organised, so that we could enjoy together the snow of Zakopane, practicing winter sports, visiting the city, or walking on the top of its beautiful mountains. In short, we learned about the most relevant scientific techniques, with exchange of ideas from both senior and junior colleagues, but also, we had the opportunity to share experiences and grow both humanly and scientifically, as this meeting is totally orientated to juniors. That is why we encourage you to participate in the next edition of EAACI Winter School 2025, so we recommend you to be attentive to social networks, website and other means of dissemination of EAACI and JMA.

Best regards,
The Junior Member Assembly


EAACI Patients Organisation Committee Corner



The POC Reunion in the Annual Congress 2023



The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.

Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.

Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.

The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.

Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.

Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.

The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.